Richard Bernstein Advisors LLC Sells 7,865 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Richard Bernstein Advisors cut its IQVIA stake by 64.2% in Q3, selling 7,865 shares and retaining 4,381 shares valued at about $832,000.
• Several other institutions added or initiated large positions—Eubel Brady & Suttman ($14.3M new stake), Eagle Rock up 33.6% to ~46,332 shares (~$8.8M), and Amundi boosted to ~1.28M shares (~$210.7M)—with institutional ownership at 89.62%.
• IQVIA shares were down ~4.1% at $171.21; the company beat quarterly EPS ($3.42) and revenue ($4.36B), set FY2026 EPS guidance of $12.55–$12.85, and carries a consensus "Buy" rating with a $229.13 price target.

Richard Bernstein Advisors LLC reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 64.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 4,381 shares of the medical research company's stock after selling 7,865 shares during the period. Richard Bernstein Advisors LLC's holdings in IQVIA were worth $832,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of IQV. Eubel Brady & Suttman Asset Management Inc. bought a new stake in shares of IQVIA during the 3rd quarter valued at about $14,278,000. Eagle Rock Investment Company LLC increased its stake in IQVIA by 33.6% in the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company's stock worth $8,800,000 after acquiring an additional 11,657 shares during the last quarter. OPTIMAS CAPITAL Ltd bought a new position in shares of IQVIA in the 3rd quarter valued at about $4,008,000. Amundi boosted its stake in IQVIA by 46.3% during the second quarter. Amundi now owns 1,279,817 shares of the medical research company's stock worth $210,722,000 after buying an additional 405,250 shares during the period. Finally, EDENTREE ASSET MANAGEMENT Ltd purchased a new position in shares of IQVIA during the third quarter valued at approximately $7,368,000. Institutional investors own 89.62% of the company's stock.

IQVIA Trading Down 4.1%

Shares of NYSE:IQV opened at $171.21 on Wednesday. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The company's 50 day moving average is $205.12 and its two-hundred day moving average is $207.39. The company has a market cap of $29.05 billion, a PE ratio of 21.78, a P/E/G ratio of 1.72 and a beta of 1.39. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts' consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the topic of a number of research reports. Wall Street Zen raised shares of IQVIA from a "hold" rating to a "buy" rating in a research report on Saturday, February 21st. Morgan Stanley set a $240.00 price objective on IQVIA in a report on Wednesday, February 11th. Barclays raised shares of IQVIA from an "equal weight" rating to an "overweight" rating and set a $210.00 target price on the stock in a research note on Friday, March 6th. Citigroup dropped their price target on shares of IQVIA from $230.00 to $200.00 and set a "neutral" rating on the stock in a research note on Friday, February 6th. Finally, TD Cowen upgraded IQVIA from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $174.00 to $213.00 in a research note on Monday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, IQVIA currently has a consensus rating of "Buy" and a consensus price target of $229.13.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.